Phase 3:
BAX802 in CHA with Inhibitors: A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
MO39129: A Single-arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients with Inhibitors
CONKO-011: Randomisierte Phase III Studie zum Stellenwert von Rivaroxaban zur Behandlung venöser Thrombosen bei Patienten mit aktiver maligner Erkrankung
Phase 4:
TAURUS: A MulTinational PhAse IV Study EvalUating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for RoUtine ProphylaxiS.
NIS-Idelvion: Eine prospektive, nichtinterventionelle Studie zur Beobachtung der Wirksamkeit eines rekombinanten Albumin-Fusionsproteins aus rekombinantem Blutgerinnungsfaktor IX und rekombinantem Albumin (rIX-FP) bei Patienten mit Hämophilie B
Sonstige Studien:
PROSPECT-Study: Retro- and prospective study to evaluate the prevalence of paroxysmal nocturnal hemoglobinuria (PNH) in patients with splanchnic vein thromboses (SVT)
